Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine + Zuberitamab followed by Orelabrutinib + Zuberitamab in newly diagnosed marginal zone lymphoma
ChiCTR2500115104Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Dec 2025
- Modality
- Small Molecules, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, hlx01 and orelabrutinib in marginal zone B-cell lymphoma (MZL), extranodal marginal zone B-cell lymphoma (EMZL), splenic marginal zone lymphoma (SMZL) and 1 more, sponsored by Xijing Hospital. Primary endpoint: Objective response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
bendamustinehlx01orelabrutinib
03
Conditions
marginal zone B-cell lymphoma (MZL)extranodal marginal zone B-cell lymphoma (EMZL)splenic marginal zone lymphoma (SMZL)nodal marginal zone B-cell lymphoma (NMZL)
Beyond the preview
Go deeper on ChiCTR2500115104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115104.